SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 13:42:10 2024-06-14 EDT | ||
| 3.07 EUR | +0.33% |
|
| 3 months | +49.76% | ||
| 6 months | +46.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 3.07 | +0.33% |
| 24-06-13 | 3.06 | +4.79% |
| 24-06-12 | 2.92 | -0.34% |
| 24-06-11 | 2.93 | -1.68% |
| 24-06-10 | 2.98 | -2.93% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:42 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3MTT |
| ISIN | DE000VU3MTT7 |
| Date issued | 2023-02-15 |
| Strike | 74.31 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.15 € |
|---|---|
| Lowest since issue | 0.38 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
